RARE
23.43 USD
+0.52%
Today
-2.44%
1D
Market is closed
Sun
Closed
Mon
4:30 PM ~ 11:00 PM
Tue
4:30 PM ~ 11:00 PM
Wed
4:30 PM ~ 11:00 PM
Thu
4:30 PM ~ 11:00 PM
Fri
4:30 PM ~ 11:00 PM
Sat
Closed
Information
Name
Ultragenyx Pharmaceutical Leveraged
Currency
USD
Standard Leverage
1X
Enhanced Leverage
3X
Overnight Fees Buy
-0.0191%
Overnight Fees Sell
0.0024%
Market Cap
2.21B
Avg Daily Volume
2.59M
52 Week High
42.37 USD
52 Week Low
18.29 USD
Trading Hours
See hours
Overnight Fees Calculator
| Daily Overnight Fee % | Daily Overnight Fee $ | |
|---|---|---|
| BUYS | -0.01910% | $(0.191) |
| SELLS | 0.00240% | $0.024 |
*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.
Business Summary
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
Top News
Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
tradingview.com
1w ago
Alcoa
-0.55%
ADMA.Biologics
-3.12%
Adient
-1.17%
Alaska_Air
-1.01%
Autoliv
+0.24%
Apollo
-2.49%
Butterfly_Network
-0.97%
BiogenIDEC
-2.24%
BostonSc
+0.70%
Blackstone
-1.66%
Coeur
+2.59%
Century.Aluminum
+1.02%
Carlyle_Group
-1.79%
ColgatePal
-0.52%
CrowdStrike
-4.36%
Chevron
-0.53%
Devon
+0.23%
Expedia
-1.01%
Flextronic
+2.34%
GM.Motors
+0.53%
Group1Auto
+0.01%
Hecla.Mining
+0.73%
RobinHood
-1.55%
Insmed
-3.03%
KKR&Co
-1.65%
Meta
+0.08%
NewmontM
+2.35%
Novavax
-5.52%
Occidental
+0.00%
ProPetro
+1.47%
Quanta
+0.66%
Ultragenyx
-2.44%
SoFiTech
-0.12%
Spire
-0.20%
Seagate
+0.14%
Sysco
-3.15%
UnitedTherapeutics
-0.48%
ExxonMobil
-1.24%
BUZZ-U.S. STOCKS ON THE MOVE-Sysco, Crowdstrike, GM
reuters.com
1w ago
Alcoa
-0.55%
ADMA.Biologics
-3.12%
Adient
-1.17%
Alaska_Air
-1.01%
Autoliv
+0.24%
Butterfly_Network
-0.97%
BiogenIDEC
-2.24%
BostonSc
+0.70%
Coeur
+2.59%
Century.Aluminum
+1.02%
ColgatePal
-0.52%
CrowdStrike
-4.36%
Chevron
-0.53%
Devon
+0.23%
Expedia
-1.01%
GM.Motors
+0.53%
Group1Auto
+0.01%
Hecla.Mining
+0.73%
Insmed
-3.03%
Meta
+0.08%
NewmontM
+2.35%
Novavax
-5.52%
Occidental
+0.00%
Quanta
+0.66%
Ultragenyx
-2.44%
Spire
-0.20%
Seagate
+0.14%
Sysco
-3.15%
UnitedTherapeutics
-0.48%
ExxonMobil
-1.24%
BUZZ-U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrike
reuters.com
1w ago
Show more
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.
